Interview with the Founder and President of AptamiR Therapeutics, Dr. Marc Thibonnier

AptamiR Therapeutics is a US based preclinical-stage biotech company developing new therapies that target fat accumulation, inflammation, and necrosis to cure related cardiometabolic disorders (obesity, dyslipidemia, diabetes, and metabolic dysfunction-associated fatty liver disease), without altering brain functions, but improving patients’ quality of life. AptamiR uses the concept of One Drug-Multiple Targets to develop microRNA targeting oligonucleotide therapeutics (ONTs) which simultaneously modulate several target genes in complex diseases.